257 320
Table 2 – Diagnostic performance of prebiopsy multiparametric MRI using biopsy findings as reference standard
Study
Overall PCa
prevalence (%)
Reporting
level
Multiparametric MRI performance for PCa detection
Definition of csPCa csPCa prevalence
Multiparametric MRI performance for csPCa detection
TN
FN
TP
FP
NPV
PPV
TN
FN
TP
FP
NPV
PPV
Hauth (2015)
[25]45.7
Patient 6
1
42
45
85.7%
48.3%
Low grade: GS 6
High grade: GS 7
NR
NR
NR
NR
NR
NR
NR
Lesion 59
13
55
73
81.9%
43%
Lamb (2015)
[36]
65.9
Patient 23
22
92
36
51.1%
71.9%
GS 7
50.9%
31
14
71
57
68.9%
55.5%
Brock (2015)
[15]
42.3
Patient 17
7
56
88
70.8%
SBx: 38.8%
TBx: 22.2%
Duo: 44.4%
Epstein: GS
>
6 and/
or max CCL 50%
24.4%
SBx: 21 SBx: 3 SBx: 38
TBx: 27
duo: 47
SBx: 106
TBx: 117
duo: 97
87.5%
SBx: 26.4%
TBx: 18.8%
duo: 32.6%
Grenabo Bergdahl
(2016)
[22]
33.7
Patient 36
7
19
21
83.7%
47.5%
Clinically insignificant
PCa: T1c, PSAd
<
0.15,
GS
<
7, 2 positive
cores, and unilateral
cancer
NR
NR
NR
NR
NR
NR
NR
Wang (2015)
[58]
58
Patient 165
8
332
81
95.4%
80.4%
NR
NR
NR
NR
NR
NR
NR
NR
Pepe (2015)
[41]
37
Patient 23
8
29
40
74.2%
42%
GS 7 or GS 6 with
CCL 50%
NR
NR
NR
NR
NR
100%
55.8%
Panebianco
(2015)
[39]
74.7
Patient Group A
(satBx): 104
Group A
(satBx): 43
Group A: 186 Group A: 22 Group A
(satBx):
70.7%
Group
A: 89.4%
NR
60%
Group A:
147
Group A:
0
Group A:
183
Group A:
25
Group A:
100%
Group A:
88%
Group B
(TRUSGB NR
TRUS G
satBx): 93
Group B
(TRUSGB
NR TRUS G
satBx): 37
Group B:
417 before
and 425 after
satBx
Group B:
23/440 and
15/440
after satBx.
Group B
(TRUSGB–
TRUS
G satBx):
71.5%
Group B:
94.8% before
and 96.6%
after satBx
71.9%
Group B:
130
Group B:
0
Group B:
410
Group B:
30
Group B:
100%
Group B:
93.2%
Radtke (2015)
[46]
51
Patient
2/5: 80
3: 103
4: 138
= 5: 142
2/5: 18
3/5: 38
4/5: 78
= 5/5: 126
2/5: 132
3/5: 112
4/5: 72
= 5/5: 24
2/5: 64
3/5: 41
4/5: 6
= 5/5: 2
2/5: 81.6%
3/5: 73.1%
4/5: 63.9%
= 5/5: 53%
2/5: 67.4%
3/5: 73.2%
4/5: 92.3%
= 5/5: 92.3%
GS 7
29.3%
2/5: 91
3/5: 124
4/5: 183
= 5/5: 203
2/5: 7
3/5: 17
4/5: 33
= 5/5: 65
2/5: 79
3/5: 69
4/5: 53
= 5/5: 21
2/5: 117
3/5: 84
4/5: 25
= 5/5: 5
2/5: 92.2%
3/5: 87.9%
4/5: 84.7%
= 5/5: 75.8%
2/5: 40.3%
3/5: 45.1%
4/5: 68%
= 5/5: 80.7%
Itatani (2014)
[27]
13
Patient 168
25
NR
NR
87%
NR
(1) PSAd 0.1 or
GP 4/5 or 3/6 pos
cores; max CCL
<
50%
(2) PSAd 0.15 or
GP 4/5 or max core
length invasion
<
3 mm
(min 6 cores)
NR
NR
NR
NR
NR
NR
NR
Porpiglia
(2014)
[44]
30.6
Patient 107
5
47
11
95.5%
81%
NR
NR
NR
NR
NR
NR
NR
NR
Thompson
(2014)
[56]
61.3
Patient 35
16
76
23
68.6%
76.7%
Moderate or high risk
Moderate risk: GS 7
(GP4
>
5%) and
<
50%
of positive cores or
GS 6–7 (GP4 5%)
and either 30% of
positive cores or
max core length
invasion 8 mm
High risk: GS 7
(GP4
>
5%); 50% +
cores or GS 8
34%
49
2
49
50
96%
49.5%
Pokorny (2014)
[43]
63.7
Patient
3/5: 56
4/5: 74
3/5: 25
4/5: 40
3/5: 101
4/5: 86
3/5: 41
4/5: 23
3/5: 69.1%
4/5: 64.9%
3/5: 71.1%
4/5: 78.9%
NR
NR
NR
NR
NR
NR
NR
NR
Petrillo (2014)
[42]
18.4
Patient 56
4
21
55
93%
28%
NR
NR
NR
NR
NR
NR
NR
NR
Javali (2014)
[29]16.4
Patient 49
1
22
68
98%
24.4%
NR
NR
NR
NR
NR
NR
NR
NR
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
257